Background & aim: Liraglutide has used for treatment of obesity and type 2 diabetes, which are main factors of infertility. Regarding that, uterus as the most important organ reproductive system is under vulnerable, particularly by chemical drugs, in this research the effects of Liraglutide on uterine tissue changes and Estradiol and FSH hormones in NMRI mice in In vivo condition has been investigated.
Methods: This experimental study has been done on 28 adult female NMRI mice (8 to 12 weeks) that have been selected with body weight between 25 and 30 grams. Female mice were randomly divided into four groups (including 7 mice): control, sham and two experimental groups. Control mice
received no treatment, experimental and sham groups were injected Liraglutide with 0.6 and 1.8 mg/kg density and solution for 30 days respectively. All injection were daily and subcutaneously. After 30 days injection, the mice were deeply anesthetized and in addition to blood sampling, mice’s uterus was removed and the one-third of right middle part of the uterus has been investigated as tissue studies. Following histochemical staining, the samples were studied using light and transmission electron microcopies. The collected data were analyzed using one-way analyses (ANOVA) and Tukey test.
Results: The results of using Liraglutide has been shown mice’s weight of experimental groups (1 and 2), compared with sham and control groups, have marked decrease (p<0.01) and (p<0.001) respectively. Also, uterus’s layers (from lumen until last layer) and lumen diameter, have marked decrease (p<0.05) and (p<0.01) respectively in experimental groups. In experimental group 2 thickness of the perimetrium has marked decrease (p<0.05), also Endometrium’s thickness in experimental groups 1 and 2, compared with sham and control groups, has shown marked decrease (p<0.01) and (p<0.001) respectively. In addition the number of uterus glands have marked increased (p<0.05) and (p<0.05) in experimental groups 1 and 2 respectively and their diameters increased in two groups. Furthermore, the values of estradiol and FSH hormones have decreased and increased respectively.
Conclusion: Treatment with Liraglutide associated with weight and uterine tissue’s thickness reduction. According to endocrine disorders, which probably is caused due to the incretin structure of the drug, also estradiol decreasing that is a female hormone, reproductive age will be limited by using Liraglutide.